-
Date:
21 May 2025
-
Location:
Room 2.2.12 - Faculty of Sciences of the University of Lisbon
-
Schedule:
12h00 (Lisbon time)
-
Lecturer or Responsible:
Eduardo da Veiga Beltrame, Assistant Professor of Computational Biology at Mohamed bin Zayed University of Artificial Intelligence
One of the most exciting consequences of the growth of single cell omics technologies is their use in new experimental designs. Beyond atlases, longitudinal studies with many timepoints are also yielding unprecedented volumes and formats of data. Driven by steadily decreasing sequencing costs and streamlined experimental workflows, single cell omics technologies are now widely used from basic biological research to drug discovery and clinical studies. I will present an overview of the emerging data and AI-models landscape in the field, together with novel clinical study designs enabled by lowering cost and complexity barriers. I will discuss emerging research directions for working with these growing volumes of single cell omics data at the newly established School of Digital Public Health at Mohamed bin Zayed University of Artificial Intelligence in Abu Dhabi, and exciting opportunities at the intersection of artificial intelligence applied to biological data.
Eduardo da Veiga Beltrame
Eduardo da Veiga Beltrame is an Assistant Professor of Computational Biology at Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). His main research interest is on developing methods and tools for working with biological data generated by single cell omics technologies and corresponding applications in advancing precision medicine. Beltrame holds a Ph.D. in bioengineering from Caltech, where his primary research focus was on the development of experimental and computational methods and tools for single cell RNA sequencing and their application to answering biological questions. Prior to joining MBZUAI, he was bioinformatics lead at ImYoo, a biotechnology startup spun out of Caltech research that executes decentralized immune studies using single cell omics. Before ImYoo, Beltrame was founding scientist at Retro Biosciences, a biotechnology startup developing ageing-related therapeutics. He is also a visiting scholar at UC Berkeley School of Education, working on a research partnership with innovative STEM education programs in Brazil.
